Identification of pre-treatment HBV DNA markers that are predictive of response to lamivudine therapy in patients infected with HBV precore variants.

被引：0
|
作者：
Korba, B
Smedile, A
Rizzetto, M
Lagget, M
Gerin, J
Ciancio, A
机构：
[1] Georgetown Univ, Rockville, MD USA
[2] Osped San Giovanni Battista, Dept Gastroenterol, Turin, Italy
来源：
ANTIVIRAL RESEARCH | 2003年 / 57卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
11
引用
下载
收藏
页码：A43 / A43
页数：1
相关论文
共 50 条
  • [21] Entecavir plus lamivudine as an alternative treatment for co-infected HBV/HIV patients with toxicity on tenofovir therapy
    Fontecha-Ortega, Maria
    Munoz-Mendoza, Vanesa
    Monsalvo, Marta
    Mateos, Marisa
    Angel Rodriguez-Sagrado, Miguel
    Gomez, Cristina
    Luis Casado, Jose
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [22] Kinetics of viral resistance and serum HBV DNA in patients under lamivudine therapy.
    Peignoux, MM
    Gervais, A
    Castelnau, C
    Boyer, N
    Pouteau, M
    Pham, BN
    Marcellin, P
    HEPATOLOGY, 2003, 38 (04) : 719A - 719A
  • [23] High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study
    Gonen, Can
    Gunduz, Feyza
    Doganay, Levent
    Enc, Feruze Y.
    Yegin, Ender G.
    Ahishali, Emel
    Erdem, Emrullah
    Sokmen, Mehmet
    Tuncer, Ilyas
    Ozdogan, Osman
    JOURNAL OF DIGESTIVE DISEASES, 2015, 16 (05) : 286 - 292
  • [24] The virological response of serum HBV DNA in patients with chronic hepatitis B after treatment with adefovir dipivixil or lamivudine
    Chen, Fuhua
    Wan, Mobin
    Zhang, Qian
    Liang, Xuesong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A123 - A123
  • [25] Clinical pathogenicity of lamivudine resistant hepatitis B virus (HBV) is related to the pre-treatment (wildtype) status.
    Dan, YY
    Lee, YM
    Lim, LL
    Wai, CT
    Lim, SG
    HEPATOLOGY, 2001, 34 (04) : 623A - 623A
  • [26] Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment
    Yuen, Man-Fung
    Sablon, Erwin
    Libbrecht, Evelien
    Van de Velde, Hilde
    Wong, Danny Ka-Ho
    Fung, James
    Wong, Benjamin Chun-Yu
    Lai, Ching-Lung
    ANTIVIRAL THERAPY, 2006, 11 (06) : 779 - 786
  • [27] Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy
    van Boemmel, Florian
    Zoellner, Bernhard
    Sarrazin, Christoph
    Spengler, Ulrich
    Hueppe, Dietrich
    Moeller, Bernd
    Feucht, Heinz-Hubert
    Wiedenmann, Bertram
    Berg, Thomas
    HEPATOLOGY, 2006, 44 (02) : 318 - 325
  • [28] Monitoring lamivudine therapy in HBV-infected patients by the quantity and structures of circulating viral nucleic acids
    张伟
    Hans Jrg Hacker
    Maria Mildenberger
    Claus H.Schrder
    苏勤
    Military Medical Research, 2003, (03) : 2 - 174
  • [29] EPIDEMIOLOGY OF HBV INFECTION IN A COHORT OF UGANDAN HIV-INFECTED PATIENTS AND RATE AND PATTERN OF LAMIVUDINE-RESISTANT HBV INFECTION IN PATIENTS RECEIVING ANTIRETROVIRAL THERAPY
    Calisti, G.
    Muhindo, R.
    Boum, Y.
    Wilson, L. A.
    Foster, G. M.
    Geretti, A. M.
    Bhagani, S.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S432 - S432
  • [30] Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy
    Calisti, G.
    Muhindo, R.
    Boum, Y.
    Wilson, L.
    Fink, D.
    Foster, G.
    Geretti, A.
    Bhagani, S.
    HIV MEDICINE, 2014, 15 : 139 - 139
12345